MoonLake Immunotherapeutics MLTX
Regular-session close
Pre-market · Nov 20, 7:57 AM ET
- YTD
- -16.31%
- 1 year
- -18.54%
5D -1.51 (-12.04%)
- Market cap
- 938.73M
- EPS (ttm)
- -3.66
- Shares out
- 85.11M
- Forward P/E
- -3.68
- YTD return
- -16.31%
- 1-year return
- -18.54%
- 50-day average
- 11.93
- 200-day average
- 16.28
- Enterprise value
- 698.48M
- Price / book
- 2.79
- Volume
- 1.41M
- Avg volume
- 1.64M
- Open
- 10.90
- Previous close
- 10.79
- Day's range
- 10.85 – 11.69
- 52-week range
- 9.46 – 23.29
- Beta
- 1.13
- Analysts
- Buy
- Price target
- 30.29 (+174.6%)
- Earnings date
- Feb 24, 2027
Key statistics
- Free cash flow
- -146.75M
- Total cash
- 498.46M
- Total debt
- 101.62M
- Return on equity
- -81.47%
- Short % of float
- 8.87%
Fundamental scorecard
4 of 25 checks passed on MLTX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 6.00
- Target (mean)
- 30.29
- Target (high)
- 57.00
- Strong buy1
- Buy11
- Hold2
- Sell2
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate -0.87464.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | -0.84 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.83257 | -0.93 | -0.10 | -11.70% |
| Aug 10, 2026 | Jun 30, 2026 | -0.90859 | -0.84 | +0.07 | +7.55% |
| May 11, 2026 | Mar 31, 2026 | -0.91 | -0.98 | -0.07 | -7.69% |
| Feb 25, 2026 | Dec 31, 2025 | -0.92 | -0.92 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | -0.89 | -1.10 | -0.21 | -23.60% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 1, 2026 | Leerink Partners | main | Outperform | Outperform |
| Jun 9, 2026 | BTIG | reit | Buy | Buy |
| Jun 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Switzerland
- Website
- moonlaketx.com
News
Your note
Sign in to keep a note on MLTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BODENSTEDT MATTHIAS | Chief Financial Officer | Sale | Jun 21, 2026 | 1,115,440 |
| BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 30, 2026 | 0 |
| CHEN BIHUA X. | Former | Sale | Sep 29, 2025 | 0 |
| MOUKHEIBIR CATHERINE | Director | Sale | Jul 2, 2025 | 0 |
| REICH KRISTIAN | Officer | Sale | Jul 26, 2026 | 0 |
| SANTOS DA SILVA JORGE | Chief Executive Officer | Sale | Jul 9, 2026 | 2,774,890 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 18.80% | 16,001,284 | 200.02M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.22% | 6,999,025 | 87.49M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 5.03% | 4,280,624 | 53.51M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 3.95% | 3,365,507 | 42.07M | Jun 29, 2026 |
| Cormorant Asset Management, LP | 3.77% | 3,205,433 | 40.07M | Jun 29, 2026 |
| Jupiter Topco LLC | 3.63% | 3,085,906 | 38.57M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 1.90% | 1,614,289 | 20.18M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1.08% | 918,586 | 11.48M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.93% | 792,072 | 9.90M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 0.71% | 605,474 | 7.57M | Jun 29, 2026 |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 0.41% | 350,134 | 4.38M | Jun 29, 2026 |
| T. Rowe Price Exch-Trd Fd.s, Inc.-T Rowe Price Capital Appreciation Eq | 0.20% | 167,768 | 2.10M | Jun 29, 2026 |
